Intermittent intravenous pantoprazole and continuous cimetidine infusion: Effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease

Journal of Trauma - Injury, Infection and Critical Care

Volumn 64, Issue 5, 2008, Pages 1202-1210

  Somberg, Lewis ^a   Morris Jr , John ^b   Fantus, Richard ^c   Graepel, Jay ^d   Field, Brian G ^d   Lynn, Richard ^d   Karlstadt, Robyn ^d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^d PFIZER INC   (United States)

Author keywords

Cimetidine; Gastric pH; Pantoprazole; Stress related mucosal disease; Upper gastrointestinal bleeding

Indexed keywords

CIMETIDINE; PANTOPRAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FEVER; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE UNIT; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MUCOSAL DISEASE; MULTICENTER STUDY; NEUROLEPTIC MALIGNANT SYNDROME; OBSTRUCTIVE JAUNDICE; PHLEBITIS; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; STOMACH ACID; STOMACH PH; STRESS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; CIMETIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRIC ACID; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; MALE; PILOT PROJECTS; STRESS;

EID: 43449108303     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e31815e40b5     Document Type: Article

References (27)

1. Lucas CE, Sugawa C, Riddle J, et al. Natural history and surgical dilemma of "stress" gastric bleeding. Arch Surg. 1971;102:266-273.
2. Marrone GC, Silen W. Pathogenesis, diagnosis and treatment of acute gastric mucosal lesions. Clin Gastroenterol. 1984;13:635-650.
3. Spirt MJ. Stress-related mucosal disease (SMRD). Acute Care of the Abdomen. 1st ed. Baltimore, MD: Williams & Wilkins, 1998;73-86.
4. Skillman JJ, Bushnell LS, Goldman H, Silen W. Respiratory failure, hypotension, sepsis, and jaundice. A clinical syndrome associated with lethal hemorrhage from acute stress ulceration of the stomach. Am J Surg. 1969;117:523-530.
5. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994;330:377-381.
6. Schuster DP, Rowley H, Feinstein S, et al. Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med. 1984;76:623-630.
7. Hastings PR, Skillman JJ, Bushnell LS, Silen W. Antacid titration in the prevention of acute gastrointestinal bleeding: a controlled, randomized trial in 100 critically ill patients. N Engl J Med. 1978;298:1041-1045.
8. Martin LF, Booth FV, Karlstadt RG, et al. Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med. 1993;21:19-30.
9. Conrad SA, Gabrielli A, Margolis B, et al. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med. 2005;33:760-765.
10. Brunner G, Chang J. Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled trial. Digestion. 1990;45:217-225.
11. Geus W, de Haas J, Sier J, et al. Effect of intravenous omeprazole 80 mg once daily and intravenous ranitidine 50 mg qid on intragastric pH in postoperative intensive care unit patients [abstract]. Gastroenterology. 1996;110;A115.
12. Wurzer H, Schutze K, Bethke T, et al. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Hepatogastroenterology. 1999;46:1809-1815.
13. Metz DC, Pratha V, Martin P, et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2000;95:626-633.
14. Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 2000;118:696-704.
15. Pratha V, Hogan DL, Lane JR, et al. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults. Dig Dis Sci. 2006;51:123-131.
16. Pratha V, Lynn RB, Karlstadt RG, et al. Gastric pH above 2.5 is of limited use as a measure of acid inhibition [abstract]. Am J Gastroenterol. 2003;98:S42.
17. Rigaud D, Chastre J, Accary JP, et al. Intragastric pH profile during acute respiratory failure in patients with chronic obstructive pulmonary disease. Effect of ranitidine and enteral feeding. Chest. 1986;90:58-63.
18. Azevedo JR, Soares MG, Silva G, Palacio G. Prevention of stress ulcer bleeding in high risk patients: comparison of three drugs [abstract]. Crit Care Med. 1999;27:A41.
19. Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med. 1987;317:1376-1382.
20. Cook DJ, Laine LA, Guyatt GH, Raffin TA. Nosocomial pneumonia and the role of gastric pH. A meta-analysis. Chest. 1991;100:7-13.
21. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med. 1996;153:1711-1725.
22. Phillips JO, Metzler MH, Palmieri TL, et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med. 1996;24:1793-1800.
23. Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma. 1998;44:527-533.
24. Phillips JO, Metzler MH, Huckfeldt RE, Olsen K. A multicenter, prospective, randomized clinical trial of continuous infusion I.V. ranitidine vs. omeprazole suspension in the prophylaxis of stress ulcers [abstract]. Crit Care Med. 1998;26:A101.
25. Netzer P, Gaia C, Sandoz M, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol. 1999;94:351-357.
26. Wilder-Smith C, Halter F, Ernst T, et al. Loss of acid suppression during dosing with H2-receptor antagonists. Aliment Pharmacol Ther. 1990;4(suppl 1):15-27.
27. Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther. 1994;8:193-201.